GLP-1 Medication Switch Guide
Compare Your Current GLP-1 Medication With the One You're Considering
Considering switching GLP-1 medications?
The GLPIANS GLP-1 Dose Switch Guide helps you organize your current medication and dose, identify the medication you are considering, understand the target medication's labeled dosing pathway, review relevant clinical evidence, and prepare questions for your healthcare professional.
It does not invent a replacement dose or create a personalized prescription.
Quick Answer
What does the GLPIANS GLP-1 Dose Switch Guide do?
It is an evidence-aware educational medication-switching guide designed to help you compare your current GLP-1-related medication with another medication you are considering.
The guide helps you:
- identify your current medication
- record your current dose or exact compounded-label wording
- select a target medication
- identify the reason for considering a switch
- understand whether an official 1:1 conversion is established
- review the target medication's labeled dosing pathway
- understand relevant clinical evidence
- understand what the evidence does not establish
- prepare questions for your prescriber
- create a structured GLP-1 switch discussion summary
Does it calculate my new GLP-1 dose?
No.
The guide intentionally does not generate an individualized replacement dose, prescription, or titration schedule.
That limitation is a core safety feature—not a missing feature.
What Is the GLPIANS GLP-1 Dose Switch Guide?
The GLPIANS GLP-1 Dose Switch Guide is an evidence-aware educational utility for people considering a change between GLP-1-related medications.
The tool takes information about your current treatment and organizes it alongside information about the medication you are considering.
Its purpose is not to produce a deceptively simple milligram conversion.
Instead, it helps answer a more useful question:
What should I understand and discuss with my healthcare professional before considering this GLP-1 medication switch?
The guide separates:
Current medication
from
Current dose context
from
Target medication
from
Labeled dosing information
from
Clinical evidence
from
Individual medical decision-making
That separation is fundamental to how the tool works.
Why GLP-1 Medication Switching Is More Complicated Than a Dose Conversion
A medication-switching question can sound simple:
“I take this dose now. What is the equivalent dose of the other medication?”
But different GLP-1-related medications can have different:
- active ingredients
- products
- FDA-approved indications
- labeled dosing schedules
- titration pathways
- dose ranges
- routes of administration
- clinical evidence
- product-specific instructions
For compounded products, there can also be additional variation in concentration and how the dose is expressed.
That means a simple:
Current dose → replacement dose
formula can create a false impression of certainty.
The GLPIANS approach is instead:
Current medication + current dose context → target medication → labeled dosing + evidence + conversion status + prescriber questions
The GLPIANS Approach in One View
| What You Provide | What the Guide Does | What the Guide Does Not Do |
|---|---|---|
| Current medication | Identifies the medication/product context | Does not prescribe |
| Current dose | Records dose context | Does not automatically calculate a replacement dose |
| Target medication | Identifies the medication being considered | Does not select your medication for you |
| Reason for switching | Adds scenario context | Does not use the reason to calculate a dose |
| Compounded-label wording | Preserves the exact label context | Does not guess concentration |
| Clinical evidence | Provides relevant evidence context | Does not turn trial results into personal instructions |
| Target labeled dosing | Shows the labeled pathway | Does not tell you which dose is personally appropriate |
| Your questions | Creates a discussion summary | Does not replace your prescriber |
Which Medications and Products Does the Tool Support?
The current production tool supports six medication/product choices:
| Medication / Product | Active Ingredient | Product Type | Route |
|---|---|---|---|
| Wegovy injection | Semaglutide | Brand | Subcutaneous injection |
| Ozempic | Semaglutide | Brand | Subcutaneous injection |
| Zepbound | Tirzepatide | Brand | Subcutaneous injection |
| Mounjaro | Tirzepatide | Brand | Subcutaneous injection |
| Compounded semaglutide | Semaglutide | Compounded | Product-specific |
| Compounded tirzepatide | Tirzepatide | Compounded | Product-specific |
The guide deliberately keeps the products separate.
Having the same active ingredient does not automatically mean that two products should be treated as interchangeable for an individual medication switch.
How the GLPIANS GLP-1 Switch Guide Works
Step 1 - Select Your Current Medication
The first question is:
What are you taking now?
Select the medication or product that best matches your current treatment.
The guide then establishes the relevant medication context.
Step 2 - Enter Your Current Dose
The dose step changes depending on the product selected.
This is important because the tool does not use one generic dose field for every medication.
FDA-labeled branded products
The guide uses the applicable labeled dose options stored in its medication data layer.
Compounded products
The workflow is intentionally different.
If you select compounded semaglutide or compounded tirzepatide, the guide asks:
What does your compounded label say?
You are instructed to enter the dose exactly as written on your:
- prescription
- vial
- pharmacy label
- product instructions
For example, a label might use wording such as:
10 units
or
0.5 mg
The tool does not assume that these expressions represent a universal concentration.
Compounded GLP-1 Medication: Why the Exact Label Matters
Compounded medications require additional caution because the product and concentration may differ from an FDA-approved product.
The FDA has warned about dosing errors associated with compounded injectable semaglutide and has highlighted differences in product presentations and concentrations. FDA communications also advise healthcare professionals to be vigilant when determining dosing and titration for compounded semaglutide and tirzepatide.
For that reason, the GLPIANS tool does not create a generic compounded-dose conversion.
The safety rule is simple:
Use the exact wording on your product label. Do not guess the concentration.
The tool also allows you to indicate:
I don't have the label or I'm not sure what the dose says.
Choosing uncertainty is safer than entering a guessed number.
Important Compounded-Dose Warning
Do not assume that “units,” mg, and mL are interchangeable.
A number expressed in units does not, by itself, tell you how many milligrams of medication are present.
Likewise, a volume in mL does not establish the amount of active ingredient without knowing the relevant concentration.
The GLPIANS guide does not perform that conversion.
If you are unsure what your compounded label means, confirm the exact product, concentration, measurement instructions, and prescribed dose with your healthcare professional or dispensing pharmacy.
Step 3 - Choose Your Target Medication
The next question is:
What are you considering?
Select the medication you are discussing as a possible switch.
The tool does not allow the same medication to be selected as both the current and target medication.
Step 4 - Tell the Guide Why You Are Considering the Switch
This step is optional.
You can identify the reason that best describes your situation:
- Insurance or coverage
- Cost or access
- Medication availability
- Side-effect concerns
- Weight-loss response
- Prescriber recommendation
- Switching from a compounded medication
Important:
The reason provides context. It does not calculate a dose.
For example, selecting “insurance / coverage” does not cause the guide to recommend a medication or dose.
Review Your GLP-1 Switch
After the required information is entered, select:
Review My Switch
The guide validates the information before generating the review.
It checks that:
- a current medication has been selected
- current dose information is available
- a target medication has been selected
- the current and target medications are different
The result then follows the appropriate conversion-status pathway.
What Does “No Official 1:1 Switch Conversion” Mean?
When the relevant medications do not have an established official 1:1 conversion that the guide can use, the result explains:
No official 1:1 switch conversion
This means the guide is not going to manufacture an equivalent dose.
Instead, it presents the relevant labeled dosing and clinical evidence while keeping the individualized treatment decision with the healthcare professional.
Same Active Ingredient Does Not Automatically Mean Automatic Equivalence
Two products may contain the same active ingredient and still have different:
- product labeling
- FDA-approved indications
- dosing instructions
- delivery systems
- prescribing contexts
Therefore, the guide does not automatically turn:
same active ingredient
into
automatic switch equivalence.
The appropriate transition plan remains a clinical decision.
When a Compounded Product Is Involved
If either the current or target medication is compounded, the guide identifies:
No standardized compounded-dose conversion
The reason is that compounded products may differ in:
- concentration
- dose expression
- units
- mg
- mL
- product-specific instructions
The exact product label and prescribing instructions should therefore be reviewed with a healthcare professional.
What the Tool Is - and What It Is Not
The GLPIANS Guide Is
- An educational medication-switching guide
- A structured comparison utility
- A labeled-dosing information tool
- An evidence-context tool
- A compounded-label capture tool
- A prescriber-discussion preparation tool
- A structured summary generator
The GLPIANS Guide Is Not
- A prescription generator
- A personalized titration calculator
- An individualized dose-conversion calculator
- A clinical decision engine
- A replacement for a healthcare professional
- A universal semaglutide-to-tirzepatide conversion table
- A universal tirzepatide-to-semaglutide conversion table
- A compounded concentration calculator
Evidence Snapshot: Tirzepatide vs Semaglutide
One of the evidence sources incorporated into the guide is the SURMOUNT-5 randomized clinical trial, published in the New England Journal of Medicine in 2025.
The trial compared tirzepatide and semaglutide in adults with obesity without type 2 diabetes.
Participants received maximum-tolerated doses:
| Treatment | Maximum-Tolerated Dose Groups | Duration |
|---|---|---|
| Tirzepatide | 10 mg or 15 mg once weekly | 72 weeks |
| Semaglutide | 1.7 mg or 2.4 mg once weekly | 72 weeks |
At week 72, the reported least-squares mean percentage change in body weight was:
| Treatment | Mean Percentage Change in Body Weight at 72 Weeks |
|---|---|
| Tirzepatide | −20.2% |
| Semaglutide | −13.7% |
The study reported greater average weight reduction with tirzepatide in this study population.
Evidence source
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36.
Critical Interpretation of SURMOUNT-5
The SURMOUNT-5 results are NOT a dose-conversion chart.
The study compared treatment groups receiving maximum-tolerated doses under the trial protocol.
It did not establish:
X mg of semaglutide = Y mg of tirzepatide
for an individual patient.
Therefore:
−20.2% vs −13.7%
should be understood as a clinical-trial outcome comparison—not as a personalized medication-switching formula.
This distinction is one of the most important safety principles of the GLPIANS tool.
Clinical Evidence vs Individual Treatment Decisions
Clinical evidence can help us understand treatment outcomes across a study population.
It can provide information about:
- efficacy
- safety
- tolerability
- dose-response relationships
- treatment differences
- study populations
- adverse events
But evidence from a clinical trial does not automatically establish an individualized treatment plan.
The GLPIANS guide therefore separates:
Evidence
from
Individual medical decision-making.
Target Medication Labeled Dosing
The guide can display the labeled dosing pathway for the medication you are considering.
For example, a target medication pathway may appear as:
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
This visual sequence is intended to make the labeled dosing pathway easier to understand.
Critical distinction
Labeled dosing information is not a personalized switching recommendation.
Seeing a dose on the pathway does not mean that the guide is telling you to start at that dose.
The appropriate starting dose, titration schedule, timing, and treatment plan should be determined by your healthcare professional.
What You Receive From the GLPIANS Guide
After completing the review and unlocking the full result, you receive a structured:
GLPIANS • PRESCRIBER DISCUSSION SUMMARY
The summary organizes your situation into several sections.
Current Medication
- Medication
- Active ingredient
- Current dose or compounded-dose context
Target Medication
- Medication
- Active ingredient
- Route/product information
Dose-Conversion Status
- Appropriate conversion-status message
- Explanation of why an automatic conversion is or is not provided
Evidence Snapshot
- SURMOUNT-5 context
- Evidence visualization
- Evidence interpretation
Target Medication Labeled Dosing
- Relevant labeled dosing pathway
- Explanation of the difference between labeled information and personalized treatment
Prescriber Questions
Four structured questions are included.
Four Questions to Take to Your Prescriber
The summary provides these questions:
- What starting and titration plan is appropriate for me?
- Should my previous medication and treatment history affect the transition?
- What should I monitor during the switch?
- When should I follow up after changing medications?
These questions are designed to turn the tool into a conversation-preparation utility, rather than simply a calculator.
Your Switch Summary Can Be Used Beyond the Tool
The completed summary can be:
- copied to your notes
- pasted into an email
- saved as a PDF
- downloaded as a DOCX
- printed
- shared using supported device sharing
- used as an appointment discussion reference
The goal is to leave you with organized information—not simply a number.
What the Full Summary Helps You Say
After using the tool, you should be able to organize your situation into:
Here is what I am taking.
Here is my current dose context.
Here is what I am considering.
Here is why I am considering the change.
Here is what the guide can and cannot say about dose equivalence.
Here is the labeled dosing pathway for the target medication.
Here is the relevant clinical evidence.
Here is what that evidence does not establish.
Here are the questions I want to discuss with my healthcare professional.
That is the central purpose of the GLPIANS tool.
What the GLPIANS Guide Does NOT Do
Safety Checklist
| The Guide Does Not... | Why |
|---|---|
| Generate a personalized prescription | Prescribing is a clinical decision |
| Calculate an individualized switching dose | A universal conversion is not established for all switches |
| Convert semaglutide mg to tirzepatide mg | Different active ingredients and dosing pathways |
| Convert tirzepatide mg to semaglutide mg | Different active ingredients and dosing pathways |
| Convert compounded units to mg | Product concentration must be known |
| Convert compounded mL to mg | Product-specific concentration matters |
| Guess a compounded concentration | The exact product label is required |
| Treat trial doses as personal instructions | Clinical trials are population-level evidence |
| Tell you to stop medication | Medication changes require professional guidance |
| Tell you to combine medications | The tool is not a prescribing system |
| Replace your healthcare professional | It is an educational discussion-preparation tool |
What the GLPIANS Guide DOES Provide
| Feature | Purpose |
|---|---|
| Current medication selection | Establishes treatment context |
| Current dose capture | Records dose information |
| Exact compounded-label input | Avoids invented compounded conversions |
| Target medication selection | Defines the possible switch being discussed |
| Switch-reason context | Adds relevant scenario information |
| Conversion-status logic | Explains what the guide can and cannot establish |
| Labeled target dosing | Shows relevant labeled dosing information |
| Clinical evidence | Provides evidence context |
| SURMOUNT-5 visualization | Makes comparative evidence easier to understand |
| Research context | Separates evidence from individual treatment |
| Safety boundaries | Prevents unsupported medication instructions |
| Prescriber questions | Helps prepare for a healthcare conversation |
| Structured summary | Organizes the switching discussion |
| Copy | Makes the summary portable |
| Provides a printable record | |
| DOCX | Provides an editable document |
| Share | Makes the summary easier to communicate |
| Reset / Check Another Switch | Allows another scenario to be reviewed |
Who Is This Tool For?
The GLPIANS GLP-1 Dose Switch Guide is designed for people who:
- currently use a GLP-1-related medication
- are considering another GLP-1-related medication
- are discussing a possible treatment change
- want to understand labeled dosing information
- want to understand relevant clinical evidence
- want to prepare for a healthcare appointment
- are discussing a transition from a compounded product
- want structured questions for their prescriber
It can be especially useful when someone is tempted to reduce a complicated medication-switching question to a single “equivalent dose.”
When Should You NOT Rely on an Online Tool?
An online educational tool should not replace direct medical assessment when you need individualized care.
Talk with an appropriate healthcare professional about:
- your personal medication history
- your medical conditions
- other medicines you take
- your previous response to treatment
- side effects
- contraindications
- dose timing
- missed doses
- restarting after an interruption
- switching between products
- compounded-product instructions
- pregnancy-related considerations
- symptoms or adverse reactions
The GLPIANS guide can help organize questions for that conversation, but it cannot perform the clinical assessment itself.
GLP-1 Switching: The Information You Should Have Ready
Before discussing a possible medication change, it can be useful to have:
1. Your current medication
Know the exact product name if possible.
2. Your current dose
Use the prescribed/labeled wording.
3. Your target medication
Know which medication you are considering.
4. Your reason for the switch
For example:
- coverage
- cost
- availability
- side effects
- treatment response
- prescriber recommendation
5. Your medication history
Your healthcare professional may need information about previous treatment, titration, interruptions, and response.
The GLPIANS guide helps organize the first four elements into a structured discussion summary.
Common GLP-1 Switching Questions
Is there a universal GLP-1 dose conversion chart?
No universal conversion chart should be assumed for switching between different GLP-1-related medications.
The GLPIANS guide therefore does not generate a generic “equivalent dose” simply by comparing milligram values.
Is semaglutide equivalent to tirzepatide?
No simple milligram-for-milligram equivalence should be assumed.
Semaglutide and tirzepatide are different active ingredients with different pharmacologic and labeled dosing contexts.
Clinical evidence can compare outcomes without establishing an individualized dose conversion.
Is tirzepatide stronger than semaglutide?
“Stronger” is an oversimplification.
In SURMOUNT-5, adults with obesity without type 2 diabetes receiving maximum-tolerated tirzepatide had greater average weight reduction at 72 weeks than those receiving maximum-tolerated semaglutide.
That does not mean one medication is universally “better” for every person, nor does it create a personal dose conversion.
Does SURMOUNT-5 prove that 15 mg tirzepatide equals 2.4 mg semaglutide?
No.
Those were maximum-tolerated dose groups in the trial.
The study compared outcomes between treatment groups; it did not establish an individualized equivalence relationship.
Can I switch from Ozempic to Wegovy using the same dose?
Both products contain semaglutide, but they are separate products with their own labeling and approved uses.
The GLPIANS guide therefore does not automatically generate a replacement dose based solely on the fact that both contain semaglutide.
Discuss the appropriate transition with your prescriber.
Can I switch from Wegovy to Ozempic using the same dose?
The same principle applies.
The guide does not assume that a dose used with one product automatically becomes the appropriate dose for another product.
Product labeling and the individual's clinical situation need to be considered.
Are Mounjaro and Zepbound the same drug?
Both contain tirzepatide, but they are distinct products with different FDA-approved indications and labeling contexts.
The GLPIANS guide treats them as separate product choices.
Can I convert compounded semaglutide units into mg?
Do not guess.
The amount represented by a number of units depends on the specific product and concentration.
Use the exact wording on your label and confirm the intended dose with your healthcare professional or dispensing pharmacy.
Can I convert compounded tirzepatide mL into mg?
Not without the relevant product concentration.
A volume alone does not establish the amount of active ingredient.
The GLPIANS guide intentionally avoids guessing or creating a generic compounded conversion.
What if I do not know my compounded dose?
Do not guess.
Use the tool's uncertainty option and obtain the exact information from your prescription, vial, pharmacy label, prescriber, or dispensing pharmacy.
Does the tool tell me what dose to start after switching?
No.
The tool can display labeled dosing information for the target product, but it does not determine an individualized starting dose or titration plan.
Can the tool replace a doctor?
No.
The guide is designed to prepare you for a better healthcare conversation.
It does not diagnose, prescribe, or make individualized treatment decisions.
Evidence and Source Methodology
The GLPIANS tool is designed around a simple evidence hierarchy.
Primary / Authoritative Sources
Where relevant, the tool uses:
- FDA prescribing information
- FDA safety communications
- peer-reviewed clinical research
- primary clinical-trial publications
Why This Matters
Medication information can change.
Labels can change.
Safety information can change.
Clinical evidence can expand.
Therefore, medication-related information should always be checked against current authoritative sources.
The tool's internal data layer includes an explicit verification/version marker, and its user-facing methodology emphasizes checking current prescribing information.
Evidence Source: SURMOUNT-5
Publication: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Journal: New England Journal of Medicine
Publication year: 2025
Trial: SURMOUNT-5
Population: Adults with obesity without type 2 diabetes
Duration: 72 weeks
Tirzepatide treatment groups: Maximum-tolerated 10 mg or 15 mg once weekly
Semaglutide treatment groups: Maximum-tolerated 1.7 mg or 2.4 mg once weekly
Reported mean weight change: −20.2% with tirzepatide vs −13.7% with semaglutide
Interpretation
The findings provide comparative evidence for the studied population and treatment protocols.
They do not establish a personal medication-switching dose.
Safety Source: FDA and Compounded GLP-1 Medications
The FDA has published safety information concerning compounded injectable semaglutide and tirzepatide, including reports associated with dosing errors and concerns related to measuring and administering compounded products.
This is why the GLPIANS tool uses an exact-label workflow for compounded products rather than assuming a universal concentration.
Practical rule
If the compounded label is unclear, do not guess the conversion. Confirm it with the appropriate healthcare professional or dispensing pharmacy.
Why GLPIANS Does Not Pretend to Have a “Magic Conversion”
A simple conversion calculator may appear convenient.
But convenience is not the same as clinical validity.
The GLPIANS approach deliberately avoids turning:
- different active ingredients
- different products
- different labels
- different dosing schedules
- different concentrations
- clinical trial outcomes
into one universal number.
Instead, the guide provides:
Context + Evidence + Labeled Information + Safety Boundaries + Prescriber Questions
That is a more appropriate model for an educational switching utility.
The GLPIANS Safety Principle
When the evidence does not establish an answer, the tool does not invent one.
This principle applies throughout the experience.
If a conversion is not established:
The tool says so.
If a compounded concentration is unknown:
The tool does not guess.
If a clinical trial does not establish dose equivalence:
The tool does not turn the trial into a conversion chart.
If an individualized treatment decision is required:
The tool directs that decision to the healthcare professional.
The Complete User Journey
DISCOVER
You arrive with a question about changing GLP-1 medications.
↓
SELECT
Choose your current medication.
↓
DEFINE
Enter your current dose or exact compounded-label wording.
↓
CONSIDER
Choose the medication you are considering.
↓
CONTEXT
Optionally select your reason for considering the switch.
↓
REVIEW
Generate your evidence-aware switching review.
↓
UNDERSTAND
Review conversion status, labeled dosing, clinical evidence, and research context.
↓
SAFETY
Understand what the evidence does and does not establish.
↓
UNLOCK
Enter your name and email to access the full summary.
↓
RECEIVE
Get your GLPIANS Prescriber Discussion Summary.
↓
EXPORT
Copy, save, download, share, or print your summary.
↓
RETURN
Check another switching scenario if needed.
Your Information Is Turned Into a Structured Discussion Summary
The goal is not to leave you with a number.
The goal is to leave you with a better-organized conversation.
Your summary can bring together:
Current medication
Current dose context
Target medication
Switching reason
Conversion status
Target labeled dosing
Clinical evidence
Evidence limitations
Safety boundaries
Prescriber questions
That is the actual value of the GLPIANS tool.
Important Safety Boundary
Do not start, stop, restart, combine, or change prescription medication based solely on this guide.
The GLPIANS GLP-1 Dose Switch Guide is an educational and discussion-preparation tool.
It does not provide individualized medical advice, prescribe medication, determine a personalized switching dose, or establish an individualized dose-equivalence relationship.
Medication switching and titration decisions should be made with an appropriate healthcare professional who can consider your individual medical history, current treatment, other medications, symptoms, risks, and treatment goals.
Sources & Evidence
The principal evidence and authoritative-source categories used by the guide include:
U.S. Food and Drug Administration
FDA prescribing information and safety communications for relevant medications and compounded GLP-1 products.
New England Journal of Medicine
SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Medication Labeling
Current product labeling should always be checked because prescribing information and safety information can change.
Frequently Asked Questions
What is a GLP-1 medication switch guide?
A GLP-1 medication switch guide helps organize information about a person's current GLP-1-related medication and a medication they are considering, while providing relevant labeled dosing, evidence context, safety information, and questions for discussion with a healthcare professional.
What is the safest way to compare GLP-1 medications before switching?
Start by identifying the exact current product, current dose, target medication, and reason for the possible switch. Then review the target product's current labeling and discuss the transition with your healthcare professional.
An online guide should not be used to create an individualized prescription.
Why doesn't the GLPIANS tool calculate an equivalent dose?
Because an unsupported conversion can create false certainty.
Different medications and products can have different active ingredients, labels, dosing pathways, and clinical contexts. Compounded products can introduce additional concentration and measurement differences.
The guide therefore prioritizes evidence and safety over producing a number simply because a user requests one.
What is the difference between labeled dosing and a personalized dose?
Labeled dosing describes how a medication is approved and instructed to be used under its applicable prescribing information.
A personalized dose is a clinical decision made for a particular individual based on their circumstances.
The GLPIANS guide can provide labeled dosing context, but it does not determine the personalized treatment decision.
Does clinical evidence tell me exactly how to switch?
Not necessarily.
Clinical studies can provide evidence about treatment outcomes and safety in defined populations under defined protocols.
They do not automatically establish a personalized switching or titration schedule for every individual.
Why is compounded medication handled differently?
Compounded products can have product-specific concentrations and instructions, and the FDA has raised concerns about dosing errors involving compounded GLP-1 products.
The GLPIANS tool therefore asks users to provide the exact wording from the label instead of assuming a standardized dose expression.
Can I use the summary during my doctor's appointment?
Yes.
The summary is designed specifically to help organize the information and questions you may want to discuss with your healthcare professional.
It is a discussion aid—not a prescription.
Before You Use the Guide
Have these details available if possible:
- Your exact medication/product name
- Your current prescribed dose
- Your prescription or compounded-product label
- The medication you are considering
- The reason you are considering the change
- Relevant treatment history
- Questions you want to ask your healthcare professional
If you do not know the exact compounded dose, do not guess.
Start Your GLP-1 Switch Review
Considering a GLP-1 medication switch?
Use the GLPIANS guide to:
Identify → Organize → Compare → Understand → Prepare
Review your medication context, labeled dosing information, clinical evidence, conversion status, safety boundaries, and prescriber questions.
Check My GLP-1 Switch →
Final Reminder
A medication switch is a clinical decision—not simply a math problem.
The GLPIANS GLP-1 Dose Switch Guide is designed to help you understand the information surrounding a possible switch and prepare for a more informed conversation with your healthcare professional.
No guessed conversions.
No compounded-dose assumptions.
No trial-dose-as-prescription logic.
No automatic replacement prescription.
Just structured information, evidence context, safety boundaries, and better questions for the conversation.
Medical & Educational Disclaimer
The GLPIANS GLP-1 Dose Switch Guide is an educational information and discussion-preparation tool. It is not medical advice, diagnosis, treatment, prescribing, or a substitute for care from a qualified healthcare professional.
The guide does not provide individualized medication-switching doses, prescriptions, or personalized titration instructions.
Information displayed by the guide may include FDA-labeled dosing information and published clinical evidence. Labeled dosing and clinical-trial results should not be interpreted as individualized treatment instructions.
Always verify current prescribing information and discuss medication changes with your healthcare professional.
If you have an urgent or severe medical concern, seek appropriate medical care rather than relying on this educational tool.
About the Tool
GLPIANS GLP-1 Dose Switch Guide
An evidence-aware educational utility designed to help people organize a possible GLP-1 medication switch, understand relevant labeled dosing and clinical evidence, recognize the limits of dose equivalence, and prepare a structured discussion with a healthcare professional.
Data version: 2026.08-locked
Last verified: August 20, 2026
Evidence and product information can change. Always verify current prescribing information.
